Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
818
datasets available to search
ShareScore release 0.9.0
Dataset results
818 results for “atrophy”
Data from: White matter lesions: spatial heterogeneity, links to risk factors, cognition, genetics, atrophy
Open the record for dataset details and reuse information.
Association of gray matter atrophy patterns with clinical phenotype and progression in multiple sclerosis
Open the record for dataset details and reuse information.
Data from: Clinically relevant cranio-caudal patterns of cervical cord atrophy evolution in MS
Objectives. To characterize the distribution and regional evolution of cervical cord atrophy in multiple sclerosis (MS) patients in a multicentre dataset. Methods. MRI and clinical evaluations were acquired from 179 controls and 435 patients (35 clinically isolated syndromes [CIS], 259 relapsing-remitting [RR], 99 secondary-progressive [SP] and 42 primary-progressive [PP]MS). Sixty-nine controls and 178 patients underwent a one-year MRI and clinical follow-up. Patients were classified as clinically stable/worsened according to their disability change. Longitudinal changes of cord atrophy were investigated with linear mixed-effect models. Sample size calculations were performed using age-, sex- and site-adjusted annualized percentage normalized cord cross-sectional area (CSAn) changes..Results. Baseline CSAn was lower in MS patients vs controls (p<0.001), but not different between controls and CIS or between early RRMS (disease duration<5 years) and CIS patients. Late RRMS (disease duration>5 years) showed significant cord atrophy vs early RRMS (p=0.02). Progressive MS patients had decreased CSAn (p<0.001) vs RRMS. Atrophy was located between C1/C2 and C5 in RRMS vs CIS, and widespread along the cord in progressive MS vs RRMS, with an additional C5/C6 involvement in SPMS vs PPMS. At follow-up, CSAn decreased in all phenotypes (p<0.001), except CIS. Cord atrophy rates were highest in early RRMS and clinically worsened patients, who had a more widespread cord involvement than stable patients. The sample size per arm required to detect a 50% treatment effect was 118 for early RRMS patients. Conclusions. Cord atrophy increased in MS during one year, except for CIS. A faster atrophy contributed to explain clinical worsening.
Supplementary material - measuring atrophy in the behavioral variant of frontotemporal dementia: a multicenter study
<p><span><span><span><span><span><span><span><span><span><span><span><b>Objective:</b> To test the hypothesis that accesible and reproducible measures of atrophy may have high clinical utility for the study of patients with the behavioral variant of frontotemporal dementia (bvFTD), we determined the diagnostic and prognostic value of six previously-validated visual atrophy scales (VAS) and the Magnetic Resonance Parkinsonism Index (MRPI).</span></span></span></span></span></span></span></span></span></span></span></p> <p><span><span><span><span><span><span><span><span><span><span><span><b>Methods:</b> We gathered data from 235 patients with bvFTD and 225 age- and MRI-matched healthy controls from three centers. One hundred twenty-one bvFTD participants had underlying frontotemporal lobar degeneration (bvFTD-FTLD) and nineteen did not have FTLD (bvFTD-noFTLD). Blinded clinicians applied VAS and the MRPI was calculated with a fully-automated approach. Cortical thickness and subcortical gray matter volumes were also calculated for comparison. We used linear mixed and Cox regression models to evaluate the ability of atrophy measures to predict clinical deterioration and survival.</span></span></span></span></span></span></span></span></span></span></span></p> <p><span><span><span><span><span><span><span><span><span><span><span><b>Results: </b>The bvFTD atrophy score (sum of atrophy scores in orbitofrontal, anterior cingulate, anterior temporal, medial temporal lobe and frontal insula regions) was usefull to discriminate bvFTD-FTLD from healthy controls (AUROC=.930; 95%CI, .903 to .957) and bvFTD-FTLD from bvFTD-noFTLD (AUROC=.880; 95%CI, .787 to .972) and had similar accuracy than cortical thickness and subcortical gray matter volumes. MRPI was increased in patients with bvFTD with underlying 4R tauopathies. The bvFTD atrophy score was an independent predictor of clinical deterioration and survival in bvFTD.</span></span></span></span></span></span></span></span></span></span></span></p> <p><span><span><span><span><span><span><span><span><span><span><span><b>Conclusions:</b> In bvFTD, the bvFTD atrophy score can increase the diagnostic certainty of underlying FTLD and predict disease progression. Moreover, the MRPI can identify bvFTD participants with an increased risk of underlying 4R tauopathies.</span></span></span></span></span></span></span></span></span></span></span></p>
Supplementary figures for: Respiratory trajectories in type 2 and 3 Spinal muscular atrophy in the iSMAC cohort study
<p>Objective. To describe the respiratory trajectories and their correlation with motor function in an international paediatric cohort of patients with type 2 and non-ambulant type 3 spinal muscular atrophy (SMA).</p> <p>Methods. Eight-year retrospective observational study of patients in the iSMAc natural history study. We retrieved anthropometrics, forced vital capacity (FVC) absolute, FVC% predicted (FVC%P.), Non-Invasive ventilation (NIV) requirement. Hammersmith functional motor scale (HFMS) and Revised performance of upper limb (RULM) were correlated with respiratory function. We excluded patients in interventional clinical trials and on Nusinersen commercial therapy.</p> <p>Results. There were 437 patients with SMA: 348 type 2, 89 non-ambulant type 3. Mean age at first visit was 6.9(±4.4) and 11.1(±4) years. In SMA type 2 FVC%P declined by 4.2%/year from 5 to 13 years, followed by a slower decline (1.0%/year). In type 3 FVC%P declined by 6.3%/year between 8 and 13 years, followed by a slower decline (0.9%/year). 39% SMA type 2 and 9% type 3 required NIV at median age 5.0(1.8-16.6) and 15.1(13.8-16.3) years. 84% SMA type 2 and 80% type 3 had scoliosis, 54% and 46% required surgery, which did not significantly affect respiratory decline. FVC%P positively correlated with HFMS and RULM in both subtypes.</p> <p>Conclusions. In SMA type 2 and non-ambulant type 3 lung function declines differently, with a common levelling after age 13 years. Lung and motor function correlated in both subtypes. Our data further defines the milder SMA phenotypes and provides novel information to benchmark the long-term efficacy of new treatments for SMA.</p>
A Study Evaluating the Effectiveness and Safety of Risdiplam Administered as an Early Intervention in Pediatric Participants With Spinal Muscular Atrophy After Gene Therapy
ClinicalTrials.gov study NCT05861986. IPD Sharing: NO. Countries: 4. Publications: 0.
Strategies to Reduce Organic Muscle Atrophy in the Intensive Care Unit
ClinicalTrials.gov study NCT02773771. IPD Sharing: NO. Countries: 0. Publications: 56.
Study to Evaluate the Safety of Intravitreal APL-2 in Patients Diagnosed With Geographic Atrophy
ClinicalTrials.gov study NCT03777332. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Hippotherapy in Children With Spinal Muscular Atrophy
ClinicalTrials.gov study NCT05341453. IPD Sharing: YES. Countries: 1. Publications: 0.
Vulvovaginal Atrophy Correction Using Neodymium Laser
ClinicalTrials.gov study NCT04735549. IPD Sharing: YES. Countries: 1. Publications: 0.
A Study of Lampalizumab Intravitreal Injections Administered Every Two Weeks or Every Four Weeks to Participants With Geographic Atrophy
ClinicalTrials.gov study NCT02288559. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Role of MSCT Volumetry in Assessment of Brain Atrophy in Septic Patients
ClinicalTrials.gov study NCT06112119. IPD Sharing: UNDECIDED. Countries: 0. Publications: 1.
Evaluation of Therapeutic Response in Spinal Muscular Atrophy Using Multispectral Optoacoustic Tomography (MSOT) and Magnetic Resonance Imaging (MRI)
ClinicalTrials.gov study NCT04262570. IPD Sharing: YES. Countries: 1. Publications: 0.
Metformin for the Minimization of Geographic Atrophy Progression in Patients With AMD
ClinicalTrials.gov study NCT02684578. IPD Sharing: NO. Countries: 1. Publications: 0.
A Pilot Therapeutic Trial Using Hydroxyurea in Type II and Type III Spinal Muscular Atrophy Patients
ClinicalTrials.gov study NCT00568802. IPD Sharing: Not stated. Countries: 1. Publications: 0.
A Pilot Therapeutic Trial Using Hydroxyurea in Type I Spinal Muscular Atrophy Patients
ClinicalTrials.gov study NCT00568698. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Clinical Trial of Sodium Phenylbutyrate in Children With Spinal Muscular Atrophy Type I
ClinicalTrials.gov study NCT00439218. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Gyrate Atrophy of the Choroid and Retina
ClinicalTrials.gov study NCT00001166. IPD Sharing: Not stated. Countries: 1. Publications: 3.
Fluocinolone Acetonide Intravitreal Inserts in Geographic Atrophy
ClinicalTrials.gov study NCT00695318. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Parenchymal Sparing Hepatectomy in Post-chemotherapy Liver Atrophy
ClinicalTrials.gov study NCT06329700. IPD Sharing: YES. Countries: 0. Publications: 4.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.